To investigated whether Tumor-Suppressing Multi-Enterobacteria improves the responsiveness of immunotherapy targeting the PD-1/PD-L1 axis in hepatocellular carcinoma, we established the murine hepatocellular carcinoma H22 cell line-derived xenograft subcutaneous tumor. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.